Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo

Månsson, Marianne LU ; Kalies, Inge ; Bergström, Göran ; Schmidt, Caroline ; Legnehed, Anne ; Hultén, Lillemor Mattsson ; Amrot-Fors, Lena ; Gustafsson, David and Knecht, Wolfgang LU (2014) In Scientific Reports 4.
Abstract

Lipoprotein (a) [Lp(a)] is a low density lipoprotein (LDL) with one apolipoprotein (a) molecule bound to the apolipoprotein B-100 of LDL. Lp(a) is an independent risk factor for cardiovascular disease (CVD). However, the relationship of Lp(a) to diabetes and metabolic syndrome, both known for increased CVD risk, is controversial. In a population based study on type two diabetes mellitus (T2DM) development in women, Lp(a) plasma levels showed the well known skewed distribution without any relation to diabetes or impaired glucose tolerance. A modified clot lysis assay on a subset of 274 subjects showed significantly increased clot lysis times in T2DM subjects, despite inhibition of PAI-1 and TAFI. Lp(a) plasma levels significantly... (More)

Lipoprotein (a) [Lp(a)] is a low density lipoprotein (LDL) with one apolipoprotein (a) molecule bound to the apolipoprotein B-100 of LDL. Lp(a) is an independent risk factor for cardiovascular disease (CVD). However, the relationship of Lp(a) to diabetes and metabolic syndrome, both known for increased CVD risk, is controversial. In a population based study on type two diabetes mellitus (T2DM) development in women, Lp(a) plasma levels showed the well known skewed distribution without any relation to diabetes or impaired glucose tolerance. A modified clot lysis assay on a subset of 274 subjects showed significantly increased clot lysis times in T2DM subjects, despite inhibition of PAI-1 and TAFI. Lp(a) plasma levels significantly increased the maximal peak height of the clot lysis curve, indicating a change in clot structure. In this study Lp(a) is not related to the development of T2DM but may affect clot structure ex vivo without a prolongation of the clot lysis time.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
publishing date
type
Contribution to journal
publication status
published
keywords
Aged, Analysis of Variance, Blood Coagulation, Blood Coagulation Tests, Carboxypeptidase B2/blood, Diabetes Mellitus, Type 2/blood, Female, Fibrinolysis, Humans, Lipoprotein(a)/blood, Middle Aged, Plasminogen Activator Inhibitor 1/metabolism
in
Scientific Reports
volume
4
article number
5318
pages
7 pages
publisher
Nature Publishing Group
external identifiers
  • scopus:84902770314
  • pmid:24937703
ISSN
2045-2322
DOI
10.1038/srep05318
language
English
LU publication?
no
id
24d417ef-bd0e-4d46-8068-b3fb85ed4d64
date added to LUP
2019-05-16 21:54:48
date last changed
2024-01-01 05:21:04
@article{24d417ef-bd0e-4d46-8068-b3fb85ed4d64,
  abstract     = {{<p>Lipoprotein (a) [Lp(a)] is a low density lipoprotein (LDL) with one apolipoprotein (a) molecule bound to the apolipoprotein B-100 of LDL. Lp(a) is an independent risk factor for cardiovascular disease (CVD). However, the relationship of Lp(a) to diabetes and metabolic syndrome, both known for increased CVD risk, is controversial. In a population based study on type two diabetes mellitus (T2DM) development in women, Lp(a) plasma levels showed the well known skewed distribution without any relation to diabetes or impaired glucose tolerance. A modified clot lysis assay on a subset of 274 subjects showed significantly increased clot lysis times in T2DM subjects, despite inhibition of PAI-1 and TAFI. Lp(a) plasma levels significantly increased the maximal peak height of the clot lysis curve, indicating a change in clot structure. In this study Lp(a) is not related to the development of T2DM but may affect clot structure ex vivo without a prolongation of the clot lysis time. </p>}},
  author       = {{Månsson, Marianne and Kalies, Inge and Bergström, Göran and Schmidt, Caroline and Legnehed, Anne and Hultén, Lillemor Mattsson and Amrot-Fors, Lena and Gustafsson, David and Knecht, Wolfgang}},
  issn         = {{2045-2322}},
  keywords     = {{Aged; Analysis of Variance; Blood Coagulation; Blood Coagulation Tests; Carboxypeptidase B2/blood; Diabetes Mellitus, Type 2/blood; Female; Fibrinolysis; Humans; Lipoprotein(a)/blood; Middle Aged; Plasminogen Activator Inhibitor 1/metabolism}},
  language     = {{eng}},
  month        = {{06}},
  publisher    = {{Nature Publishing Group}},
  series       = {{Scientific Reports}},
  title        = {{Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo}},
  url          = {{http://dx.doi.org/10.1038/srep05318}},
  doi          = {{10.1038/srep05318}},
  volume       = {{4}},
  year         = {{2014}},
}